The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease

Journal of Hepatology

Volumn 44, Issue 6, 2006, Pages 1175-1185

  Thabut, Dominique ^a   Naveau, Sylvie ^b   Charlotte, Frederic ^a   Massard, Julien ^a   Ratziu, Vlad ^a   Imbert Bismut, Françoise ^a   Cazals Hatem, Dominique ^c   Abella, Annie ^b   Messous, Djamila ^a   Beuzen, Fabienne ^b   Munteanu, Mona ^d   Taieb, Julien ^a   Moreau, Richard ^e   Lebrec, Didier ^e   Poynard, Thierry ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

^c BEAUJON HOSPITAL   (France)

^d Biopredictive   (France)

^e CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

Author keywords

ActiTest; Alanine aminotransferase; Alcoholic liver disease; Alcoholic steato hepatitis; Alpha macroglobulin; Apolipoprotein A I; AshTest; Aspartate aminotransferase; Biopsy; Fibrosis; FibroTest; Haptoglobin; Necrosis activity; ROC curve

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; HAPTOGLOBIN;

ADULT; ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; ALCOHOLIC FATTY LIVER; ARTICLE; CELL INFILTRATION; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

ADULT; BIOLOGICAL MARKERS; CHRONIC DISEASE; FATTY LIVER, ALCOHOLIC; FEMALE; HEPATITIS, ALCOHOLIC; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; REPRODUCIBILITY OF RESULTS;

EID: 33646471229     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2006.02.010     Document Type: Article

References (59)

1. Diehl A.M. Liver disease in alcohol abusers: clinical perspective. Alcohol 27 (2002) 7-11
2. Maher J.J. Alcoholic steatosis and steatohepatitis. Semin Gastrointest Dis 13 (2002) 31-39
3. Chikritzhs T.N., Jonas H.A., Stockwell T.R., Heale P.F., and Dietze P.M. Mortality and life-years lost due to alcohol: a comparison of acute and chronic causes. Med J Aust 174 (2001) 281-284
4. Menon K.V., Gores G.J., and Shah V.H. Pathogenesis, diagnosis, and treatment of alcoholic liver disease. Mayo Clin Proc 76 (2001) 1021-1029
5. Tome S., and Lucey M.R. Current management of alcoholic liver disease. Aliment Pharmacol Ther 19 (2004) 707-714
6. Levitsky J., and Mailliard M.E. Diagnosis and therapy of alcoholic liver disease. Semin Liver Dis 24 (2004) 233-247
7. Orrego H., Blake J.E., Blendis L.M., and Medline A. Prognosis of alcoholic cirrhosis in the presence and absence of alcoholic hepatitis. Gastroenterology 92 (1987) 208-214
8. Mathurin P., Duchatelle V., Ramond M.J., Degott C., Bedossa P., Erlinger S., et al. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology 110 (1996) 1847-1853
9. Mathurin P., Mendenhall C.L., Carithers Jr. R.L., Raymond M.J., Maddrey W.C., Garstide P., et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 36 (2002) 480-487
10. McGill D.B., Rakela J., Zinsmeister A.R., and Ott B.J. A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 99 (1990) 1396-1400
11. Poynard T., Ratziu V., and Bedossa P. Appropriateness of liver biopsy. Can J Gastroenterol 14 (2000) 543-548
12. Cadranel J.F., Rufat P., and Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the group of epidemiology of the french association for the study of the liver (AFEF). Hepatology 32 (2000) 477-481
13. Afdhal N.H. Biopsy or biomarkers: is there a gold standard for diagnosis of liver fibrosis?. Clin Chem 50 (2004) 1299-1300
14. Poynard T., Imbert-Bismut F., Munteanu M., Messous D., Myers R.P., Thabut D., et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 3 (2004) 8
15. Myers R.P., Tainturier M.H., Ratziu V., Piton A., Thibault V., Imbert-Bismut F., et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 39 (2003) 222-230
16. Poynard T, Zoulim F, Ratziu V, Degos F, Imbert-Bismut F, Deny P. Longitudinal assessment of histology surrogate markers (Fibrotest-Actitest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastenterol 2005;100:1970-1980.
17. Callewaert N., Van Vlierberghe H., Van Hecke A., Laroy W., Delanghe J., and Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nature Med 10 (2004) 429-434
18. Naveau S., Raynard B., Ratziu V., Abella A., Imbert-Bismut F., Messous D., et al. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol 3 (2005) 167-174
19. Castera L., Hartmann D.J., Chapel F., Guettier C., Mall F., Lons T., et al. Serum laminin and type IV collagen are accurate markers of histologically severe alcoholic hepatitis in patients with cirrhosis. J Hepatol 32 (2000) 412-418
20. Annoni G., Colombo M., Cantaluppi M.C., Khlat B., Lampertico P., and Rojkind M. Serum type III procollagen peptide and laminin (Lam-P1) detect alcoholic hepatitis in chronic alcohol abusers. Hepatology 9 (1989) 693-697
21. Nojgaard C., Johansen J.S., Christensen E., Skovgaard L.T., Price P.A., and Becker U. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J Hepatol 39 (2003) 179-186
22. Chossegros P. Extracellular matrix serum markers (ECMSM) in alcoholic liver disease. J Hepatol 22 (1995) 96-99
23. Halfon P., Imbert-Bismut F., Messous D., Antoniotti G., Benchetrit D., Cart-Lamy P., et al. A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. Comp Hepatol 1 (2002) 3-7
24. Imbert-Bismut F., Messous D., Thibaut V., Myers R.B., Piton A., Thabut D., et al. Intralaboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med 42 (2004) 323-333
25. Munteanu M., Messous D., Thabut D., Imbert-Bismut F., Jouys M., Massard J., et al. Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (Fibrotest) and activity (Actitest). Comp Hepatol 3 (2004) 3
26. Poynard T., Aubert A., Bedossa P., Abella A., Naveau S., Paraf F., et al. A simple biological index for detection of alcoholic liver disease in drinkers. Gastroenterology 100 (1991) 1397-1402
27. Naveau S., Giraud V., Borotto E., Aubert A., Capron F., and Chaput J.C. Excess weight risk factor for alcoholic liver disease. Hepatology 25 (1997) 108-111
28. Poynard T., Naveau S., Doffoel M., Boudjema K., Vanlemmens C., Mantion G., et al. Evaluation of efficacy of liver transplantation in alcoholic cirrhosis using matched and simulated controls: 5-year survival. J Hepatol 30 (1999) 1130-1137
29. Naveau S., Abella A., Raynard B., Balian A., Giraud V., Montembault S., et al. Tumor necrosis factor soluble receptor p55 and lipid peroxidation in patients with acute alcoholic hepatitis. Am J Gastroenterol 96 (2001) 3361-3367
30. Bedossa P., Poynard T., Naveau S., Martin E.D., Agostini H., and Chaput J.C. Observer variation in assessment of liver biopsies of alcoholic patients. Alcohol Clin Exp Res 12 (1988) 173-178
31. Poynard T., Mathurin P., Lai C.L., Guyader D., Poupon R., Tainturier M.H., et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 38 (2003) 257-265
32. Poynard T., Munteanu M., Imbert-Bismut F., Charlotte F., Thabut D., Le Calvez S., et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 50 (2004) 1344-1355
33. Hintze JL. NCSS 2003 User Guide. Number cruncher statistical systems 2003 software. NCSS, Kaysville, Utah.
34. DeLong E.R., DeLong D.M., and Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44 (1988) 837-845
35. Zhou X, Obuchowski N, McClish D. In: Statistical methods in diagnostic medicine. New York: Wiley; 2002.
36. Srikureja W., Kyulo N.L., Runyon B.A., and Hu K.Q. MELD score is a better prognostic model than Child-Turcotte-Pugh score or discriminant function score in patients with alcoholic hepatitis. J Hepatol (2005) 700-706
37. Maddrey W.C., Boitnott J.K., Bedine M.S., Weber Jr. F.L., Mezey E., and White Jr. R.I. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 75 (1978) 193-199
38. Vergani C., Trovato G., Delu A., Pietrogrande M., and Dioguardi N. Serum total lipids, lipoprotein cholesterol, and apolipoprotein A in acute viral hepatitis and chronic liver disease. J Clin Pathol 31 (1978) 772-778
39. Tada N., Nestel P.J., Fidge N., and Campbell G. Abnormal apolipoprotein composition in alcoholic hepatitis. Biochim Biophys Acta 664 (1981) 207-220
40. Poynard T., Abella A., Pignon J.P., Naveau S., Leluc R., and Chaput J.C. Apolipoprotein AI and alcoholic liver disease. Hepatology 6 (1986) 1391-1395
41. Bedossa P., Poynard T., Abella A., Aubert A., Pignon J.P., Naveau S., et al. Apolipoprotein AI is a serum and tissue marker of liver fibrosis in alcoholic patients. Alcohol Clin Exp Res 13 (1989) 829-833
42. Poynard T., Bedossa P., Mathurin P., Ratziu V., and Paradis V. Apolipoprotein A1 and hepatic fibrosis. J Hepatol 22 (1995) 107-110
43. Paradis V., Mathurin P., Ratziu V., Poynard T., and Bedossa P. Binding of apolipoprotein A-I and acetaldehyde-modified apolipoprotein A-I to liver extracellular matrix. Hepatology 23 (1996) 1232-1238
44. Paradis V., Laurent A., Mathurin P., Poynard T., Vidaud D., Vidaud M., et al. Role of liver extracellular matrix in transcriptional and post-transcriptional regulation of apolipoprotein A-I by hepatocytes. Cell Mol Biol 42 (1996) 525-534
45. Mathurin P., Vidaud D., Vidaud M., Bedossa P., Paradis V., Ratziu V., et al. Quantification of apolipoprotein A-I and B messenger RNA in heavy drinkers according to liver disease. Hepatology 23 (1996) 44-51
46. Grimbert S., Trinchet J.C., Hartmann D.J., Munz C., Garnier M., Mal F., et al. Comparison of six potential serum markers of hepatic fibrosis in alcoholic disease of the liver. Gastroenterol Clin Biol 17 (1993) 570-577
47. Coetzee G.A., Strachan A.F., van der Westhuyzen D.R., Hoppe H.C., Jeenah M.S., and de Beer F.C. Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J Biol Chem 261 (1986) 9644-9651
48. Shephard E.G., de Beer F.C., de Beer M.C., Jeenah M.S., Coetzee G.A., and van der Westhuyzen D.R. Neutrophil association and degradation of normal and acute-phase high-density lipoprotein 3. Biochem J 248 (1987) 919-926
49. Blackburn Jr. W.D., Dohlman J.G., Venkatachalapathi Y.V., Pillion D.J., Koopman W.J., Segrest J.P., et al. Apolipoprotein A-I decreases neutrophil degranulation and superoxide production. J Lipid Res 32 (1991) 1911-1918
50. Park C.T., and Wright S.D. Plasma lipopolysaccharide-binding protein is found associated with a particle containing apolipoprotein A-I, phospholipid, and factor H-related proteins. J Biol Chem 271 (1996) 18054-18060
51. Furlaneto C.J., Ribeiro F.P., Hatanaka E., Souza G.M., Cassatella M.A., and Campa A. Apolipoproteins A-I and A-II downregulate neutrophil functions. Lipids 37 (2002) 925-928
52. Cabana V.G., Feng N., Reardon C.A., Lukens J., Webb N.R., de Beer F.C., et al. Influence of apoA-I and apoE on the formation of serum amyloid A-containing lipoproteins in vivo and in vitro. J Lipid Res 45 (2004) 317-325
53. He R., Sang H., and Ye R.D. Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1/LXA4R. Blood 101 (2003) 1572-1581
54. Cogny A., Paul J.L., Atger V., Soni T., and Moatti N. Structural changes of high-density-lipoprotein apolipoproteins following incubation with human polymorphonuclear cells. Eur J Biochem 222 (1994) 965-973
55. Bergt C., Marsche G., Panzenboeck U., Heinecke J.W., Malle E., and Sattler W. Human neutrophils employ the myeloperoxidase/hydrogen peroxide/chloride system to oxidatively damage apolipoprotein A-I. Eur J Biochem 268 (2001) 3523-3531
56. Moudry R., Spycher M.O., and Doran J.E. Reconstituted high density lipoprotein modulates adherence of polymorphonuclear leukocytes to human endothelial cells. Shock 7 (1997) 175-181
57. Badolato R., Wang J.M., Stornello S.L., Ponzi A.N., Duse M., and Musso T. Serum amyloid A is an activator of PMN antimicrobial functions: induction of degranulation, phagocytosis, and enhancement of anti-Candida activity. J Leukoc Biol 67 (2000) 381-386
58. Labayle D., Chaput J.C., Albuisson F., Buffet C., Martin E., and Etienne J.P. Analyse histologique comparative des biopsies du lobe droit et du lobe gauche dans les lésions alcooliques du foie. Gastroenterol Clin Biol 3 (1979) 235-240
59. Bedossa P., Dargère D., and Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38 (2003) 1449-1457